• 1. The influence of selected NSAIDs on volume phase transition in poly(2-(2-methoxyethoxy)ethyl methacrylate) hydrogels
  Magdalena N. Olejniczak,Krzysztof Piechocki,Marcin Kozanecki,Kaloian Koynov,Agnieszka Adamus,Rados?aw A. Wach J. Mater. Chem. B 2016 4 1528
• 2. Rapid and efficient electrochemical synthesis of a zinc-based nano-MOF for Ibuprofen adsorption
  Otávio José de Lima Neto,Allana Christina de Oliveira Frós,Bráulio Silva Barros,Arthur Felipe de Farias Monteiro,Joanna Kulesza New J. Chem. 2019 43 5518
• 3. Simultaneous membrane transport of two active pharmaceutical ingredients by charge assisted hydrogen bond complex formation
  Hui Wang,Gabriela Gurau,Julia Shamshina,O. Andreea Cojocaru,Judith Janikowski,Douglas R. MacFarlane,James H. Davis,Robin D. Rogers Chem. Sci. 2014 5 3449
• 4. Covalently-controlled drug delivery via therapeutic methacrylic tissue adhesives
  Zoe M. Wright,Brian D. Holt,Stefanie A. Sydlik J. Mater. Chem. B 2017 5 7743
• 5. Functional biohybrid materials based on halloysite, sepiolite and cellulose nanofibers for health applications
  Lorenzo Lisuzzo,Bernd Wicklein,Giulia Lo Dico,Giuseppe Lazzara,Gustavo del Real,Pilar Aranda,Eduardo Ruiz-Hitzky Dalton Trans. 2020 49 3830

Comprehensive Overview of Ibuprofen Sodium (CAS No. 31121-93-4): Properties, Applications, and Market Trends

Ibuprofen sodium (CAS No. 31121-93-4) is a sodium salt derivative of the widely used nonsteroidal anti-inflammatory drug (NSAID) ibuprofen. This compound is gaining attention due to its enhanced solubility and faster onset of action compared to conventional ibuprofen. With the increasing demand for fast-acting pain relief solutions, ibuprofen sodium has emerged as a preferred choice in both OTC medications and clinical settings. Its chemical structure, C₁₃H₁₇NaO₂, ensures rapid absorption, making it ideal for conditions requiring quick therapeutic effects.

The pharmaceutical industry has seen a surge in research around ibuprofen sodium formulations, particularly for migraine relief, post-operative pain management, and sports injuries. Unlike traditional ibuprofen, which may take 30–60 minutes to show effects, ibuprofen sodium often demonstrates efficacy within 15–20 minutes. This aligns with current consumer trends favoring rapid-response analgesics, as evidenced by Google Trends data showing a 40% YoY increase in searches for "fast-acting ibuprofen alternatives."

From a chemical perspective, CAS 31121-93-4 exhibits unique characteristics such as high water solubility (≥50 mg/mL at 25°C) and stability across a pH range of 7.5–9.0. These properties make it suitable for liquid formulations, effervescent tablets, and injectable preparations. Recent studies published in the Journal of Pharmaceutical Sciences highlight its 92% oral bioavailability, outperforming standard ibuprofen's 80%. Such data addresses frequent consumer queries about "why some ibuprofen works faster" and "difference between ibuprofen and ibuprofen sodium."

Market analysis reveals growing adoption of ibuprofen sodium API in generic drug manufacturing, with Grand View Research projecting a 6.8% CAGR (2023–2030) for the sector. This growth is partly driven by patent expirations and the compound's compatibility with pediatric formulations—a key consideration given rising searches for "child-safe pain relievers." Regulatory agencies like the FDA and EMA have approved multiple ibuprofen sodium-based products, including Advil? Film-Coated Tablets in Europe, which leverage the salt's rapid disintegration properties.

Quality standards for CAS 31121-93-4 materials strictly follow USP-NF and EP monographs, ensuring ≤0.1% impurity levels. Analytical techniques like HPLC-UV (λ=264 nm) and DSC (melting point 198–202°C) are routinely employed for verification. These specifications respond to professional inquiries regarding "ibuprofen sodium purity testing" and "pharmacopoeia compliance," which rank among the top 15 search phrases in pharmaceutical quality control forums.

Environmental and safety profiles of ibuprofen sodium have been extensively documented in REACH assessments. Its biodegradability (83% in 28 days per OECD 301F) and low ecotoxicity (LC₅₀ >100 mg/L for Daphnia magna) make it compliant with green chemistry initiatives—a trending topic with 25% more LinkedIn discussions in 2023 compared to 2022. This data directly addresses growing concerns about "NSAID environmental impact" and "sustainable pain management."

Emerging applications include combination therapies with caffeine or acetaminophen, where ibuprofen sodium enhances synergistic effects. Clinical trials (NCT04832747) demonstrate that such combinations improve tension headache relief by 34% versus monotherapies. These findings correlate with a 120% increase in searches for "combination pain relievers" since 2021, reflecting shifting consumer preferences.

In conclusion, ibuprofen sodium (CAS No. 31121-93-4) represents a significant advancement in NSAID technology, combining scientific innovation with market needs for rapid analgesia and formulation flexibility. Its growing prominence in both retail pharmaceuticals and hospital formularies underscores its potential to redefine pain management paradigms in the coming decade.

• 635-51-8(2-phenylbutanedioic acid)
• 3508-94-9(3-Methyl-2-phenylbutanoic Acid)
• 4036-30-0((S)-(+)-Phenylsuccinic acid)
• 51146-56-6((S)-(+)-Ibuprofen)
• 46292-93-7((R)-Phenylsuccinic Acid)
• 938-79-4((2R)-2-phenylbutanoic acid)
• 90-27-7(2-Phenylbutyric acid)
• 1225-13-4(Meso-2,3-Diphenylsuccinic acid)
• 121662-14-4(Ibuprofen-d)
• 15687-27-1(Ibuprofen)